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Abstract 
Objective 
To provide an overview of non-parenteral clonidine formulations and assess the feasibility of their 
use for paediatric sedation. 
Methods 
A literature search was conducted using electronic databases and a combination of search terms. 
Forty articles met the inclusion criteria. Publications were grouped into different dosage forms and 
assessed for their potential application for sedation of children in intensive care. 
Key findings 
Several routes of clonidine administration have been investigated for numerous indications in 
children, including perioperative sedation and analgesia. These include oral liquids, tablets, oral 
transmucosal systems, nasal sprays and rectal suspensions. Conflicting studies on oral transmucosal 
clonidine formulations suggest that further research is required to fully establish efficacy. Nasal 
sprays and rectal suspensions have the advantages of rapid onset of action and potential for dose 
flexibility, but predictable absorption is difficult to obtain. 
Conclusions 
Provided age-appropriate strengths are available, IV formulations remain the most predictable in 
terms of bioavailability and flexible in terms of dose adjustment. However, as with all routes, 
down-titration is difficult given the long half-life of clonidine. Oral transmucosal systems, nasal 
sprays and rectal suspensions have potential in a less acute setting, but significant clinical work is 
required to elucidate a full pharmacokinetic and pharmacodynamic profile. 
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Introduction  
Clonidine hydrochloride is commonly used off-label in paediatric anaesthesia and intensive care 
medicine. It acts by reducing intraoperative anaesthetic requirements and metabolic responses to 
surgery due to its effects on central sympathetic outflow and centrally based analgesia 
mechanisms.[1] Clonidine is recommended for the sedation of critically ill children in Paediatric 
Intensive Care Units (PICUs) by the United Kingdom and German consensus guidelines,[2; 3] as 
well as in clinical guidelines used at hospitals across Europe. 
 
Clonidine hydrochloride is an imidazoline α-2 adrenoceptor agonist. It is licensed in adults for the 
treatment of hypertension, migraine and menopausal flushing.[4] It has an aqueous solubility of 
about 77 mg/mL[5] and is considered either Class I (high solubility/high permeability) or Class III 
(high solubility/low permeability) under the Biopharmaceutics Classification System (BCS).[6] 
Although clonidine is sometimes classified as a BCS Class III drug, many years of successful 
therapy in hypertensive adults as a solid oral dosage form would suggest that permeability does not 
limit oral bioavailability. In the United Kingdom, clonidine is available in tablets (25mcg), 
ampoules for injection (150mcg/1mL) and as a transdermal delivery system that delivers 0.1, 0.2, or 
0.3 mg clonidine per day.[7] However, much smaller intravenous infusion doses are required for 
sedation in children. A limited dose finding study in PICU has shown an intravenous infusion rate 
of 1-2 mcg/kg/h provides dose dependent sedation without haemodynamic compromise in terms of 
heart rate, blood pressure or cardiac output.[8]  
 
Rapid and effective sedation is often required in an emergency paediatric setting. Consequently, 
delivery is often by the intravenous (IV) route.[9] An advantage of IV drug delivery is that the dose 
immediately enters systemic circulation and can be adjusted by altering the flow rate of an IV 
pump. This means that loading doses and maintenance doses can be continuously administered. 
However, as clonidine is not licensed for this indication, there are no age-specific formulations 
available. To address this, a large, multi-centre clinical trial investigating clonidine for the sedation 
of paediatric patients in the intensive care unit (CloSed project, see ClinicalTrials.gov, ref. 
NCT02509273) is currently underway and age-appropriate formulations have been developed 
(http://www.closed-fp7.eu). However, in a less acute setting IV drug delivery is not always ideal, 
particularly for children already subject to the stress of a hospital environment. This review aimed 
to explore alternative, non-injectable clonidine formulations that have been developed and their 
feasibility as candidates for use in the sedation of children. By highlighting possible formulations 
and knowledge gaps pertaining to these, novel alternatives will be identified in the hope that a less 
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invasive clonidine formulation may be developed for the sedation of children in an emergency 
setting. 
 
Method 
Search strategy 
To determine the types of clonidine formulations used for sedation, relevant journal articles written 
in English between January 1946 and December 2014 were considered. Reviews, conferences and 
book citations were excluded so only original research articles and case reports were eligible for 
inclusion. Three databases - Scopus, OvidSP (including Embase and Ovid Medline) and Web of 
Science were searched using the independent keywords ‘clonidine’ AND ‘drug administration’, 
with subject headings: ‘Drug administration’ OR ‘inhalational drug administration’ OR 
‘intradermal drug administration’ OR ‘intranasal drug administration’ OR ‘oral drug 
administration’ OR ‘rectal drug administration’ OR ‘sublingual drug administration’ OR ‘topical 
drug administration’ OR ‘transdermal drug administration’. These searches were then combined 
and duplicates were removed.  
Eligibility criteria and process of selection  
The title and abstract of each publication was screened. Publications were excluded if the route of 
administration was by injection or if the dosage form was a commercially available unmodified 
tablet (unless the population group was paediatric), because the focal point of this review was to 
assess the feasibility of alternate clonidine dosage forms for the sedation of children. If the dosage 
form or route of administration was not specified, then the indication was assessed and studies of 
hypertension, opioid withdrawal or growth hormone response were excluded on the basis that they 
were likely to use commercially available dosage forms. Publications that did not involve a 
clonidine formulation were also excluded.  
Data extraction and analyses  
Dosage form, route of administration, dose, number of subjects and age range, excipients (if listed) 
and indication of each of the selected publications were recorded. Following the screening process, 
the full-texts of publications that met the criteria were examined and a second screening step took 
place. Publications were grouped and dosage forms were assessed for their potential application for 
sedation of children in an intensive care setting.  
 
Non-parenteral clonidine preparations 
The title and abstract of 3978 publications were screened and from these, the full-texts of 66 
publications were assessed for eligibility following the criteria stated above.  After 26 papers were 
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excluded for being outside of the parameters of interest, 40 remained and were included in the final 
review. 
 
This literature review involved a lengthy screening process, with 3978 studies initially screened for 
inclusion.  Though it would have been ideal to reduce this large number of hits, this proved difficult 
because automatically omitting certain key words, such as ‘intravenous’ excluded all studies, 
including those comparing intravenous clonidine administration with alternative dosage forms.  In 
addition, in many of these studies the route of clonidine administration was not a focal point of the 
publication and therefore, not specified in the title or abstract. This made the initial screening phase 
a lengthy process that required some assumptions, resulting in the exclusion of studies of 
hypertension, opioid withdrawal or growth hormone response where dosage form or route of 
administration was not specified on the basis that they were likely to use commercially available 
dosage forms.  
 
A summary of the different clonidine dosage forms is presented in Table 1. The following sections 
discuss these dosage forms in further detail. 
 
Oral route  
Orally, clonidine is well absorbed with good central nervous system penetration. However, a major 
limitation of oral clonidine for the sedation of children in a hospital setting is its slow onset of 
action, with peak plasma concentrations being reached after 60 to 90 minutes.[51] 
Oral tablets 
Many children are unable to swallow ‘adult size’ tablets[52-54] and this is augmented in an 
intensive care setting. Previous studies investigating the use of clonidine tablets in children have 
tended to focus on older individuals and chronic conditions.[15; 16; 19; 20] Mini tablets (around 
4mm diameter) have shown promise as dosing platforms for children.[55-57] Recent research has 
shown that full-term neonates aged between 2 and 28 days accepted uncoated mini tablets equally 
well as syrup.[58] However, to date there have been no papers published on the use of small-sized 
tablet formulations for clonidine. Such a formulation would need to cater for children of a wide 
weight range, and the consumption of multiple tablets would be unavoidable. In addition, onset of 
action remains a limitation and in an intensive care setting, even swallowing mini tablets may not 
be possible. 
Oral liquids 
Several studies have investigated liquid formulations of clonidine hydrochloride.[21; 22; 24-35] 
Various sources of clonidine have been used, as well as a range of sweeteners to improve 
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palatability (Table 2). Oral liquid formulations have the advantage of dose flexibility but excipients 
are required to mask the taste of the drug. When extemporaneously compounding any formulation, 
the risk for error is greatly increased. For example, one case study reported a five-year-old child 
who received a 1000-fold overdose of clonidine due to a calculation error when formulating an oral 
liquid.[59] 
 
Although oral liquids have been used perioperatively in children, their major limitation is slow 
onset of action. Mahajan and colleagues found that although the quality of sedation was superior 
with clonidine as opposed to midazolam, onset of sedation was significantly slower, at 38.5 ± 12.6 
minutes.[26] Larsson and co-authors found that the maximum plasma concentration following 
administration of 4mcg/kg clonidine in an apple fruit drink was 0.77mcg/L (Tmax 1.04 hours). Oral 
bioavailability in children aged 3 to 10 years old was found to be 55.4% (CV 6.4%; 95% CI 0.469, 
0.654), which is lower than adults.[28] This has implications for the dosing regimen, meaning that 
higher doses would need to be administered in order to achieve a therapeutic effect comparable to 
IV administration. 
 
Arenas-López et al. studied the relationship between oral dose via nasogastric tube, plasma-profile 
and sedative effects in 24 children (median [interquartile range] age 3 months [1.3-15.9], weight 
5.0kg [4.5-5.6]) requiring intubation for primary respiratory failure and likely to need mechanical 
ventilation for longer than 72 hours in the PICU.[23] The clonidine dose range used in this study 
was 3-5mcg/kg, which was extrapolated from previous paediatric premedication studies [60] and 
adult schedules on a dose/kg basis. This produced an initial temporal increase in plasma 
concentration that appeared to plateau by 41 hours, suggesting that steady state values were 
achieved by this time. Clonidine was administered as an oral solution that was manufactured under 
a Medicines & Healthcare Products Regulatory Agency (MHRA) “specials” manufacturing licence, 
but it was not stated whether clonidine was obtained from raw powder, crushed tablets or the 
commercially available IV formulation. 
 
Oral transmucosal route 
Oral transmucosal drug delivery is an alternative method of systemic drug delivery that offers 
several advantages over both injectable and enteral methods. Oral transmucosal drug delivery 
bypasses hepatic first pass metabolism and avoids degradation or metabolism by gastric juices and 
enzymes in the gastrointestinal tract.[61] The oral mucosa has a relatively high permeability and 
abundant blood supply, which allows for rapid transport to the systemic circulation.[62] For some 
drugs, this results in rapid onset of action via a more comfortable and convenient delivery route 
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compared with the intravenous route. However, in order to be successful for transmucosal drug 
delivery, a drug candidate must have good lipophilicity and high water solubility at physiological 
pH. Irritancy to the oral cavity can also be a problem. Clonidine is lipophilic and as such, has the 
potential to be delivered by this route. In addition, the concentration required for therapeutic effect 
is in the microgram range, meaning that drug loading would not be a problem. However, 
developing strengths that consider the wide body weight range of paediatrics, from birth up to 18-
year-olds, as well as loading doses and dose changes, is challenging with single use solid dosage 
forms and requires careful consideration. 
 
Clonidine lollipops have been investigated for their potential as pre-anaesthetic medication.[36; 37] 
One study found that satisfactory sedation was achieved in ten out of 16 patients but that patients 
aged 1-3 years were unable to consume a sufficient dose for adequate sedation.[36] In addition, the 
time taken to consume a lollipop could be variable between patients. A further study found that 
orally disintegrating tablet formulations were superior to lollipops in reaching satisfactory 
sedation.[37] A summary of oral transmucosal formulations identified in the literature search are 
presented in Table 3. 
 
Sublingual tablets have been considered as an alternative to oral administration for adults with 
hypertension.[38; 39] Gilkeson and Delaney suggested that the apparent effectiveness, simplicity 
and safety of sublingual clonidine would make it a useful alternative in the treatment of 
hypertension.[39] Cunningham and colleagues found that although clonidine was well absorbed 
sublingually, the pharmacokinetic and pharmacodynamic profiles were not significantly different 
from the oral route, meaning that the onset of action was still between 60 and 180 minutes.[38] 
 
Lollipop formulations identified in this literature search were sweetened with sucrose and starch 
syrup, but excipients used to improve the palatability of the ODTs and sublingual tablets were not 
described.[36; 37] No study provided data on taste acceptability from patients. In addition, studies 
involved children over the age of 12 months and the sample sizes in each study were small (Table 
3). Further research into oral mucosal clonidine formulations is required to fully establish efficacy. 
 
Rectal route 
Another enteral route, the rectal route, has many advantages in the delivery of medicines to children 
because there is no need to swallow or mask the taste of the dosage form. However, there are also 
challenges associated with the development and use of rectal drug formulations, which may explain 
the paucity of commercially available rectal preparations.[63] Rectal administration can lead to 
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erratic absorption and because of this, must be fully evaluated for safety and efficacy in addition to 
bioavailability studies. Further, there are issues surrounding patient perception, including cultural 
barriers, understanding and attitudes.[64; 65]  
 
Clonidine has been rectally administered by diluting a commercial IV solution (Catapresan, 150 
mcg/mL) in normal saline to 10 mcg/mL before administering using a syringe adapted to a cut 
suction catheter. Following administration of 2.5 mcg/kg clonidine to ten children (14-48 months 
old weighing 10-20kg), leaking of the solution was not a problem and a high bioavailability (95%) 
was demonstrated. The median maximum plasma concentration was 0.77ng/ml, half-life was 12.5 
hours and volume of distribution 0.961 L/kg.[43] 
 
Peak plasma concentrations are reportedly reached 40-50 minutes following rectal clonidine 
administration.[66] This has been supported by a case study in an adult that reported crushed 
clonidine tablets mixed with sorbitol and given rectally via a catheter effectively controlled 
hypertension, with an initial response noted within 45 minutes.[44] The development of a liquid 
suspension administered by a catheter allows for easy dose adaptation, compared to semi-solid 
dosage forms (such as suppositories), which do not allow dose flexibility. However, sorbitol is an 
osmotic laxative and therefore, not an appropriate vehicle for a rectal suspension. 
 
Nasal route 
Intranasal drug administration is an easy and relatively non-invasive method of drug administration 
that avoids hepatic first pass metabolism. The nasal cavity consists of thin, vascularised epithelium, 
offering fast absorption and rapid onset of therapeutic effect for many drugs. Babhair and 
colleagues compared the bioavailability of IV and nasal clonidine in rodents and found that peak 
plasma concentration via the nasal route was reached within ten minutes.[48] However, Almenrader 
and colleagues compared an oral liquid formulation of clonidine with nasal drops and found that 
although sedation was equivalent in the two groups, nasal drops resulted in a slower onset of 
action.[21] In addition, it may be difficult to control the dose of drops administered, which could 
result in altered absorption. The use of an aerosol spray for intranasal delivery has been shown to be 
preferable, likely as a result of the superior spread of the drug into the nasal cavity and subsequent 
improved absorption.[45] Clonidine hydrochloride is highly water soluble, so theoretically a high 
concentration would be feasible.  However, direct transport of clonidine from the nasal mucosa into 
systemic circulation has been shown to be unpredictable and erratic.[47] Further, the volume of 
drug that can be administered intranasally is limited and may be a factor in variability. The 
maximum volume for adults is 100-200 µL per nostril, but this is likely to be considerably smaller 
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and more varied in children. Excess fluid would run out of the nose and be lost, or flow down the 
back of the throat and essentially undergo metabolism via the oral route. In addition, several factors 
including drug dose, preparation, method of administration, state of the nasal mucosa and definition 
of sedation may play a role in the variation seen across studies.[46] 
 
Larsson and colleagues found that nasal aerosol clonidine delivery at a concentration of 3-8 µg/kg 
did not result in sufficient preoperative sedation within 30 minutes of sedation,[45] yet other studies 
of similar concentrations found that sedation was adequate within 30 minutes.[21; 22; 46] In 
summary, further research is required to ascertain the dosing regimen required to achieve sufficient 
sedation within 30 minutes.  
 
Pulmonary route 
The inhaled route of clonidine administration has been investigated for its effect on 
bronchoconstriction. Although animal studies have shown promise for this indication, to date 
human studies have not, possibly due to differences in the neural control pathways.[49] Systemic 
effects of inhaled clonidine such as sedation and hypotension were not reported, so the impact of 
inhaled clonidine on sedation is not currently known. If it is possible to achieve sedation by 
pulmonary clonidine delivery, administration may be achieved by nebulisation. 
 
Transdermal route 
The literature search resulted in a paucity of transdermal formulations. Transdermal clonidine is 
licensed for the treatment of hypertension and the lack of hits was most likely due to the exclusion 
of hypertension studies on the basis that the focus of this review was on the formulation and testing 
of (in particular extemporaneous) clonidine preparations for use in children. The safety and efficacy 
of the commercially available clonidine transdermal system has not been established in paediatrics, 
though it has been reportedly used off-label for the management of hypertension, Attention deficit 
hyperactivity disorder (ADHD) and neuropathic pain.[67] The patches are programmed to release 
clonidine at an approximately constant rate over a seven-day period, and the absence of rebound 
hypertension after the patch is removed suggests that following application, a depot of clonidine in 
the skin becomes a self-tapering source.[68] This is not ideal when sedation is no longer required. 
Further, it takes up to four days to achieve steady state plasma concentrations,[67; 68] so is not a 
feasible dosage form for acute sedation.  
 
Conclusions 
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Several different routes of clonidine administration have been investigated for numerous indications 
in children, including perioperative sedation and analgesia. This report discussed the feasibility of 
alternative, less invasive dosage forms in a paediatric intensive care setting, where the IV route is 
common. Oral liquid dosage forms have potential as alternatives to IV administration of clonidine 
in an intensive care setting, offering reasonable dose flexibility and individualisation despite their 
slower onset of action. However, the patient must be conscious in order to swallow the liquid. Oral 
tablets do not allow dosing flexibility and are not suitable for young children. Clonidine has the 
potential to be delivered via the oral transmucosal route, but appropriate strengths need to be 
elucidated and further formulation studies are required to ensure appropriate taste masking. Nasal 
sprays and rectal suspensions have the advantage of rapid onset of action and potential for dose 
flexibility. In addition, dosing may be maintained while the child is sedated. IV formulations remain 
the most flexible in terms of dosage accuracy and control, and are the easiest to administer in an 
intensive care setting. Significant formulation work is required to develop an effective dosage form 
and elucidate a full pharmacokinetic and pharmacodynamic profile of clonidine administered via all 
of these routes.  
 
Acknowledgements 
This project has received funding from the European Union’s Seventh Framework Programme for 
research, technological development and demonstration under grant agreement n° 602453. 
 
References 
1. Nishina K et al. Effects of oral clonidine premedication on plasma glucose and lipid 
homeostasis associated with exogenous glucose infusion in children. Anesthesiology 1998; 
4: 922-927. 
2. Martin J et al. Evidence and consensus-based German guidelines for the management of 
analgesia, sedation and delirium in intensive care - short version. Ger Med Sci 2010: Doc02. 
3. Playfor S et al. Consensus guidelines on sedation   and analgesia in critically ill children. 
Intensive Care Med 2006; 8: 1125-1136. 
4. Joint Formulary Committee. British National Formulary, 57th edn. London: British Medical 
Association and Royal Pharmaceutical Society of Great Britain, 2008. 
5. O'neil MJ ed. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals,  
Cambridge: Royal Society of Chemistry, 2013. 
6. Dahan A et al. Prediction of solubility and permeability class membership: provisional BCS 
classification of the world’s top oral drugs. AAPS J 2009; 4: 740-746. 
7. Datapharm. Electronic Medicines Compendium (eMC),  Leatherhead, UK, 2016.  
https://www.medicines.org.uk/emc/search (accessed 07 March 2016). 
8. Ambrose C et al. Intravenous clonidine infusion in critically ill children: dose-dependent 
sedative effects and cardiovascular stability. Br J Anaesth 2000; 6: 794-6. 
9. Sasada M, Smith S. Drugs in Anaesthesia and Intensive Care, 3rd edn. Oxford: Oxford 
University Press, 2003. 
10. Wolf A et al. Prospective multicentre randomised, double-blind, equivalence study 
comparing clonidine and midazolam as intravenous sedative agents in critically ill children: 
 11 
the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care 
Sedation) study. Health Technol Assess 2014; 71. 
11. Schmidt AP et al. Effects of preanesthetic administration of midazolam, clonidine, or 
dexmedetomidine on postoperative pain and anxiety in children. Pediatr Anesth 2007; 7: 
667-674. 
12. Jahromi S et al. A comparison of the effect of oral paracetamol and clonidine on pediatric 
preoperative anxiety in adenotonsillectomy. Pak J Med Health Sci 2009; 3: 458-461. 
13. Qteshat BS. Use of oral clonidine and oral midazolam as preanesthetic medications in the 
pediatric patient undergoing tonsillectomy. RMJ 2011; 2: 114-115. 
14. Shiga M et al. Oral clonidine premedication does not change efficacy of simulated epidural 
test dose in sevoflurane-anesthetized children. Anesthesiology 2000; 4: 954. 
15. Fagermoen E et al. Clonidine in the treatment of adolescent chronic fatigue syndrome: a 
pilot study for the NorCAPITAL trial. BMC Res Notes 2012; 1: 418. 
16. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized 
controlled trial. Neurology 2002; 4: 527-36. 
17. Nair V, Mahadevan S. Randomised controlled study-efficacy of clonidine versus 
carbamazepine in children with ADHD. J Trop Pediatr 2009; 2: 116. 
18. Schvehla TJ et al. Clonidine therapy for comorbid attention deficit hyperactivity disorder 
and conduct disorder: preliminary findings in a children's inpatient unit. South Med J 1994; 
7: 692-5. 
19. Ming X et al. Use of clonidine in children with autism spectrum disorders. Brain Dev 2008; 
7: 454-460. 
20. Jaselskis CA et al. Clonidine treatment of hyperactive and impulsive children with autistic 
disorder. J Clin Psychopharmacol 1992; 5: 322-327. 
21. Almenrader N et al. Steal‐induction after clonidine premedication: a comparison of the oral 
and nasal route. Pediatr Anesth 2007; 3: 230-234. 
22. Mukherjee S et al. Clonidine premedication for paediatric patients:  A comparison of the 
oral and nasal route. J Anaesthesiol Clin Pharmacol 2010; 3: 319-322. 
23. Arenas-López S et al. Use of oral clonidine for sedation in ventilated paediatric intensive 
care patients. Intensive Care Med 2004; 8: 1625-1629. 
24. Mikawa K et al. Attenuation of the catecholamine response to tracheal intubation with oral 
clonidine in children. Can J Anaesth 1995; 10: 869-74. 
25. Almenrader N et al. Premedication in children: a comparison of oral midazolam and oral 
clonidine. Pediatr Anesth 2007; 12: 1143-1149. 
26. Mahajan RK et al. Comparison of oral clonidine and midazolam as premedications in 
children. J Clin Diagn Res 2012; 5: 870-873. 
27. Trevor S et al. A comparison of midazolam and clonidine as an oral premedication in 
pediatric patients. Saudi J Anaesth 2012; 1: 8-11. 
28. Larsson P et al. Oral bioavailability of clonidine in children. Pediatr Anesth 2011; 3: 335-
340. 
29. Mikawa K et al. Efficacy of oral clonidine premedication in children. Anesthesiology 1993; 
5: 926-931. 
30. Mikawa K et al. Oral clonidine premedication reduces vomiting in children after strabismus 
surgery. Can J Anaesth 1995; 11: 977-981. 
31. Gulhas N et al. Oral clonidine premedication does not reduce postoperative vomiting in 
children undergoing strabismus surgery. Acta Anaesthesiol Scand 2003; 1: 90-93. 
32. Levinson M, Johnson C. Stability of an extemporaneously compounded clonidine 
hydrochloride oral liquid. Am J Health Syst Pharm 1992; 1: 122-125. 
33. Mikawa K et al. Oral clonidine premedication reduces postoperative pain in children. Anesth 
Analg 1996; 2: 225. 
 12 
34. Tazeroualti N et al. Oral clonidine vs midazolam in the prevention of sevoflurane-induced 
agitation in children. a prospective, randomized, controlled trial. Br J Anaesth 2007; 5: 667-
71. 
35. Pawlik MT et al. Clonidine premedication in patients with sleep apnea syndrome: A 
randomized, double-blind, placebo-controlled study. Anesth Analg 2005; 5: 1374-1380. 
36. Sumiya K et al. Sedation and plasma concentration of clonidine hydrochloride for pre-
anesthetic medication in pediatric surgery. Biol Pharm Bull 2003; 4: 421-423. 
37. Homma M et al. Assessment of clonidine orally disintegrating tablet for pre-anesthetic 
medication in pediatric surgery. Biol Pharm Bull 2006; 2: 321-323. 
38. Cunningham FE et al. Comparative pharmacokinetics of oral versus sublingual clonidine. J 
Clin Anesth 1994; 5: 430-433. 
39. Gilkeson G, Delaney R. Effectiveness of sublingual clonidine in patients unable to take oral 
medication. Drug Intell Clin Pharm 1987; 3: 262-263. 
40. Sarisuta N et al. Effects of surfactant on release characteristics of clonidine hydrochloride 
from ethylcellulose film. Drug Dev Ind Pharm 1999; 3: 373-377. 
41. Bergendahl HT et al. Neuropeptide Y response to tracheal intubation in anaesthetized 
children: effects of clonidine vs midazolam as premedication. Br J Anaesth 1999; 3: 391-
394. 
42. Bergendahl H et al. Clonidine vs. midazolam as premedication in children undergoing 
adeno‐tonsillectomy: A prospective, randomized, controlled clinical trial. Acta Anaesthesiol 
Scand 2004; 10: 1292-1300. 
43. Lönnqvist P et al. Pharmacokinetics of clonidine after rectal administration in children. 
Anesthesiology 1994; 5: 1097-1101. 
44. Johnston R et al. The use of rectal clonidine in the perioperative period. Anesthesiology 
1986; 2: 288-290. 
45. Larsson P et al. Onset time for pharmacologic premedication with clonidine as a nasal 
aerosol: a double-blind, placebo-controlled, randomized trial. Pediatr Anesth 2012; 9: 877-
883. 
46. Mitra S et al. Intranasal clonidine vs. midazolam as premedication in children: a randomized 
controlled trial. Indian Pediatr 2014; 2: 113-118. 
47. Almenrader N et al. Absorption pharmacokinetics of clonidine nasal drops in children. 
Pediatr Anesth 2009; 3: 257-261. 
48. Babhair S et al. Comparison of intravenous and nasal bioavailability of clonidine in rodents. 
Res Commun Chem Pathol Pharmacol 1990; 2: 241-248. 
49. O'connell F et al. Effect of clonidine on induced cough and bronchoconstriction in guinea 
pigs and healthy humans. J Appl Physiol 1994; 3: 1082-1087. 
50. Lindgren BR et al. The effect of inhaled clonidine in patients with asthma. Am Rev Respir 
Dis 1986; 2: 266-269. 
51. Nishina K et al. Clonidine in paediatric anaesthesia. Pediatr Anesth 1999; 3: 187-202. 
52. Standing JF, Tuleu C. Paediatric formulations—Getting to the heart of the problem. Int J 
Pharm 2005; 1–2: 56-66. 
53. Ivanovska V et al. Pediatric drug formulations: a review of challenges and progress. 
Pediatrics 2014; 2: 361-372. 
54. Lopez FL et al. Formulation approaches to pediatric oral drug delivery: benefits and 
limitations of current platforms. Expert Opin Drug Deliv 2015; 11: 1727-1740. 
55. Spomer N et al. Acceptance of uncoated mini-tablets in young children: results from a 
prospective exploratory cross-over study. Arch Dis Child 2012; 3: 283-286. 
56. Klingmann V et al. Favorable acceptance of mini-tablets compared with syrup: 
a randomized controlled trial in infants and preschool children. J Pediatr 2013; 6: 1728-
1732. 
57. Van Riet-Nales DA et al. Acceptability of different oral formulations in infants and 
preschool children. Arch Dis Child 2013; 9: 725-731. 
 13 
58. Klingmann V et al. Acceptability of uncoated mini-tablets in neonates - a randomized 
controlled trial. J Pediatr 2015; 4: 893-896. 
59. Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in 
a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 2: 471-472. 
60. Ramesh V et al. Comparative study of oral clonidine and diazepam as premedicants in 
children. Int J Clin Pharm Th 1997; 5: 218-221. 
61. Lam JKW et al. Oral transmucosal drug delivery for pediatric use. Adv Drug Deliv Rev 
2014; 0: 50-62. 
62. Patel VF et al. Advances in oral transmucosal drug delivery. J Control Release 2011; 2: 
106-116. 
63. Jannin V et al. Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev 2014; 
0: 34-49. 
64. Hinton RL et al. Caregivers' acceptance of using artesunate suppositories for treating 
childhood malaria in Papua New Guinea. Am J Trop Med Hyg 2007; 4: 634-640. 
65. Sam-Wobo SO et al. Rectal artesunates, their utilization, and parental perception in the 
management of malaria in children from Abeokuta, southwestern Nigeria. Vector Borne 
Zoonotic Dis 2012; 2: 151-155. 
66. Lönnqvist P, Bergendahl H. Pharmacokinetics and haemodynamic response after an 
intravenous bolus injection of clonidine in children. Pediatr Anesth 1993; 6: 359-364. 
67. Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. Adv 
Drug Deliv Rev 2014: 63-82. 
68. Hunt RD et al. Clonidine in child and adolescent psychiatry. J Child Adolesc 
Psychopharmacol 1990; 1: 87-102. 
  
 14 
Table 1 Summary of the characteristics of different clonidine dosage forms. IV formulations were 
not investigated in this literature search, but an overview is presented here for reference. 
 IV Oral tablet Oral liquid Oral 
transmucosal 
Rectal  Intranasal Pulmonary 
References [9; 10] [11-20] [21-35] [36-40] [41-44] [21; 22; 45-
48] 
[49; 50] 
Ease of 
administration in 
PICU setting 
+++ 
 
+ 
 
++ 
 
+ 
 
++ 
 
++ 
 
++ 
 
Typical child 
dose 
0-3  
 µg/kg/h 
4 mcg/kg 2-4 mcg/kg 2-4 mcg/kg 2.5 mcg/kg 3-4 µg/kg 150 mcg 
(adult) 
Approximate 
onset of action 
(minutes) 
10 120 90 120 45 > 30 
(conflicting 
data)  
 
Cost of 
manufacture and 
development 
+ + + ++ + ++ ++ 
Dose 
individualisation 
& flexibility 
+++ + ++ + ++ + ++ 
Clinical/technical 
considerations 
Painful, 
difficult in 
neonates 
Requires 
ability to 
swallow 
solid 
dosage 
forms 
Suitable 
taste 
masking 
vehicle 
required. 
Patient 
must be 
conscious 
to swallow 
liquid  
Difficulty 
in dose 
adaptation 
and dose 
control 
Unpredictable 
bioavailability 
 
Variability 
of 
absorption 
Volume for 
delivery  
depends on 
device 
Systemic 
effect of 
inhaled 
clonidine 
on 
sedation 
are 
currently 
not known 
+ = low , ++ = medium +++ = high 
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Table 2 Summary of clonidine source and vehicles used in liquid formulations. 
Clonidine source Reference 
Crushed tablets [26; 27; 32] 
Catapresan injection [21; 25] 
Clonidine HCl powder [28] 
Source not specified [22; 24; 29-31; 33-35] 
Vehicle/sweetener  
Honey [26; 27] 
Apple juice [24; 28-31; 33] 
Simple Syrup [32; 34]  
Commercial ibuprofen suspension [21; 25] 
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Table 3 Summary of oral transmucosal clonidine lollipop, orodispersible tablet (ODT) and 
sublingual tablet formulations. 
Study Sumiya et al. [36] Homma et al. [37] Cunningham et al. [38] 
Clonidine 
formulation(s) 
Lollipop Lollipop, ODT Sublingual tablet 
 
Indication Premedication Sedation hypertension 
Concentration 2 or 4 mcg/kg 4 mcg/kg 0.3 mg 
Age 1 to 11 years 1 to 11 years 20 to 42 years 
Number of subjects 16 23 10 
Plasma concentration 0.36±0.05ng/ml 
(2mcg/kg group) 
0.50±0.16ng/ml 
(4mcg/kg group) 
0.42±0.21ng/ml 
(lollipop) 
0.75±0.15ng/ml (ODT) 
1.3 ± 0.2 ng/ml (Cmax) 
Time of measured 
plasma concentration 
2 h 2 h 2.3 ± 1.9 h (Tmax) 
 
